scholarly journals Prevalence of Medication Errors in Admitted Patients at the Philippine General Hospital

2017 ◽  
Vol 51 (2) ◽  
Author(s):  
Paul Matthew D. Pasco ◽  
Ruzanne M. Caro ◽  
Connie L. Cruz ◽  
Nerissa M. Dando ◽  
Iris Thiele C. Isip-Tan ◽  
...  
Keyword(s):  
Medication Errors ◽  
Chart Review ◽  
Prospective Observational Study ◽  
Adverse Drug Events ◽  
Medical Center ◽  
Inappropriate Drug ◽  
Systematic Sampling ◽  
First Year ◽  
True Prevalence ◽  
Review Study

Background. Medication errors are preventable events that can cause or lead to inappropriate drug use. Knowing the prevalence and types of errors can help us institute corrective measures and avoid adverse drug events. Objective. This study determined the prevalence of medication errors and its specific types in the four main service wards of a tertiary government training medical center. Methods. This is a retrospective, descriptive chart review study. From the master list of admissions, systematic sampling was done to retrieve the required number of charts. Relevant pages such as order sheets, nurses’ notes, therapeutic sheets were photographed. For prolonged admissions, only the first 7 days were reviewed. Each chart was evaluated by two people who then met and agreed on the errors identified. Results. The overall prevalence of medication errors is 97.8%. Pediatrics had the most (63.3/chart), followed by Medicine, OBGynecology, and Surgery (7.3/chart). The most common type of errors identified were prescribing, followed by compliance, then administration errors. Conclusion. Medication errors are present in the four main wards in our hospital. We recommend orientation of all incoming first year residents on proper ordering and prescribing of drugs, as well as a prospective observational study to determine true prevalence of all types of medication errors.

Perioperative Medication Errors and Adverse Drug Events

2018 ◽  
pp. 138-142
Keyword(s):  
Observational Study ◽  
Medication Errors ◽  
Prospective Observational Study ◽  
Adverse Drug Events ◽  
Perioperative Period ◽  
Anesthesia Care ◽  
Perioperative Medication

This case focuses on medication errors and adverse drug events occurring during the perioperative period by asking the question: What are the rates, types, severity, and preventability of medication errors (MEs) and adverse drug events (ADEs) in the perioperative setting during anesthesia care? This prospective observational study reported that approximately 1 in 20 perioperative medication administrations, and every second operation, resulted in an ME and/or an ADE. These rates are markedly higher than those reported by prior retrospective surveys. Process- and technology-based solutions may address the root causes of MEs to reduce their incidence.

scholarly journals Evaluation of Perioperative Medication Errors and Adverse Drug Events

2016 ◽  
Vol 124 (1) ◽  
pp. 25-34 ◽  
Author(s):  
Karen C. Nanji ◽  
Amit Patel ◽  
Sofia Shaikh ◽  
Diane L. Seger ◽  
David W. Bates
Keyword(s):  
Medication Errors ◽  
Adverse Drug Events ◽  
Medical Center ◽  
Academic Medical Center ◽  
Tertiary Care ◽  
Academic Medical ◽  
Study Staff ◽  
Chart Abstraction ◽  
Life Threatening ◽  
Perioperative Medication

Abstract Background The purpose of this study is to assess the rates of perioperative medication errors (MEs) and adverse drug events (ADEs) as percentages of medication administrations, to evaluate their root causes, and to formulate targeted solutions to prevent them. Methods In this prospective observational study, anesthesia-trained study staff (anesthesiologists/nurse anesthetists) observed randomly selected operations at a 1,046-bed tertiary care academic medical center to identify MEs and ADEs over 8 months. Retrospective chart abstraction was performed to flag events that were missed by observation. All events subsequently underwent review by two independent reviewers. Primary outcomes were the incidence of MEs and ADEs. Results A total of 277 operations were observed with 3,671 medication administrations of which 193 (5.3%; 95% CI, 4.5 to 6.0) involved a ME and/or ADE. Of these, 153 (79.3%) were preventable and 40 (20.7%) were nonpreventable. The events included 153 (79.3%) errors and 91 (47.2%) ADEs. Although 32 (20.9%) of the errors had little potential for harm, 51 (33.3%) led to an observed ADE and an additional 70 (45.8%) had the potential for patient harm. Of the 153 errors, 99 (64.7%) were serious, 51 (33.3%) were significant, and 3 (2.0%) were life-threatening. Conclusions One in 20 perioperative medication administrations included an ME and/or ADE. More than one third of the MEs led to observed ADEs, and the remaining two thirds had the potential for harm. These rates are markedly higher than those reported by retrospective surveys. Specific solutions exist that have the potential to decrease the incidence of perioperative MEs.

Abstract P185: Feasibility and Outcome of Pharmacist-Enhanced Stroke Rounds

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Megan J Walley ◽  
Samantha Lewis ◽  
Christa Ohana S Nobleza
Keyword(s):  
Medication Errors ◽  
Adverse Drug Events ◽  
Medical Center ◽  
Patient Centered Care ◽  
Healthcare Outcomes ◽  
Stroke Patients ◽  
Patient Centered ◽  
Cost Avoidance ◽  
Stroke Service ◽  
Centered Care

Background: Treatment of stroke patients is complex. Multidisicplinary rounds have been shown to decrease 30-day readmission rates, improve efficiency in work flow, communication between disciplines and promote patient-centered care. Pharmacy-enhanced intensive care unit rounds reduce adverse drug events (ADE) and provide real-time resource for drug selection, interaction and dosages. Reports on the feasibility of pharmacist-enhanced stroke rounds (PEnSR) and its effect on outcomes are few. Objective: Determine the effect of a pharmacy-enhanced stroke-rounds on patient and healthcare outcomes. Methods: A performance improvement analysis was done in the University of Mississippi Medical Center from September 1, 2019 to November 30, 2019. A pharmacist assigned to the stroke service performed medical reconciliation, monitored drug interaction, provided recommendations on drug choice and dosages for the stroke patients and alerts on medication errors. The primary outcome includes the proportion and severity of medication errors detected utilizing the EPIC iVent tool. The secondary outcomes include characteristics of interventions to prevent an ADE, cost-avoidance based on the errors and cost-analysis for the continued presence of a pharmacist for stroke rounds based on time spent to perform the role. A feedback-survey regarding the pharmacist was done at the end of analysis period. Results: A total of 77 interventions were performed during 2 month with a total cost avoidance of $40,250. Most common errors were minor. The most common intervention by the pharmacist was to initiate orders followed by discontinuing orders. Overall time spent daily for the stroke service was 5-hours. All residents and attendings of the stroke service were aware of the pharmacist’s presence, utilized the service and perceived that the PEnSR was beneficial. Conclusion: PEnSR was feasible and cost-effective and allows for the pharmacist to still contribute to other roles in the hospital. PEnSR also improves patient-centered care for stroke patients by preventing ADE resulting in hospital savings of ~$20,000/month. The UMMC-Stroke team has adapted PEnSR as part of the daily multidisciplinary stroke care.

scholarly journals Medication errors and adverse drug events in a UK hospital during the optimisation of electronic prescriptions: a prospective observational study

2019 ◽  
Vol 1 (8) ◽  
pp. e403-e412 ◽  
Author(s):  
Sarah P Slight ◽  
Clare L Tolley ◽  
David W Bates ◽  
Rachel Fraser ◽  
Theophile Bigirumurame ◽  
...  
Keyword(s):  
Observational Study ◽  
Medication Errors ◽  
Prospective Observational Study ◽  
Adverse Drug Events ◽  
Electronic Prescriptions

scholarly journals Potential adverse drug events and its predictors among hospitalized patients at medical center in Ethiopia: a prospective observational study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tamiru Sahilu ◽  
Mestawet Getachew ◽  
Tsegaye Melaku ◽  
Tadesse Sheleme ◽  
Duresa Abu ◽  
...  
Keyword(s):  
Observational Study ◽  
Prospective Observational Study ◽  
Adverse Drug Events ◽  
Medical Center ◽  
Statistical Significance ◽  
Tertiary Hospital ◽  
Adult Patients ◽  
Drug Event ◽  
P Value ◽  
Contributing Factors

AbstractPotential adverse drug event (PADE) is a medication error with the potential to cause associate degree injury however that does not cause any injury, either due to specific circumstances, chance, or as a result of the error being intercepted and corrected. This study aimed to assess the incidence, contributing factors, predictors, severity, and preventability of PADEs among hospitalized adult patients at Jimma Medical Center. A prospective observational study was conducted among hospitalized adult patients at a tertiary hospital in Ethiopia. Logistic regression was performed to identify factors predicting PADE occurrence. P-value < 0.05 was considered for statistical significance. A total of 319 patients were included. About 50.5% of them were females. The mean ± SD age of the participants was 43 ± 17.6 years. Ninety-four PADEs were identified. Number of medications (adjusted OR = 5.12; 95% CI: 2.01–13.05; p = 0.001), anticoagulants (adjusted OR = 2.51; 95% CI: 1.22–5.19; p = 0.013), anti-seizures (adjusted OR = 21.96; 95% CI: 6.57–73.39; p < 0.0001), anti-tuberculosis (adjusted OR = 2.2; 95% CI: 1.002–4.59, p = 0.049), and Elixhauser comorbidity Index ≤ 15 (adjusted OR = 6.24; 95% CI: 1.48–26.25, p = 0.013) were independent predictors of PADEs occurrence. About one-third of patients admitted to the hospital experienced PADEs.

A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16733-e16733
Author(s):  
Kenneth H. Yu ◽  
Andrew Eugene Hendifar ◽  
Olatunji B. Alese ◽  
Amber Draper ◽  
Maen Abdelrahim ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Real World ◽  
Chart Review ◽  
Medical Center ◽  
Ductal Adenocarcinoma ◽  
Cancer Center ◽  
Real World Data ◽  
World Data ◽  
Review Study ◽  
Liposomal Irinotecan

e16733 Background: Real-world data allows healthcare decision-makers to assess and manage therapeutic and economic options for patients, including those who would and would not have met eligibility criteria for randomized control trials (RCT) and are instead managed under usual care. This retrospective multi-academic center chart review study describes real-world characteristics and outcomes of US patients receiving liposomal irinotecan for the management of metastatic pancreatic ductal adenocarcinoma (mPDAC). Methods: Patients with mPDAC treated with liposomal irinotecan were eligible. Initiation of liposomal irinotecan defined index date; covariates assessed included clinical characteristics and treatment patterns; real-world overall survival (rwOS) was assessed via Kaplan-Meier methodology. The target enrollment is 300 patients. The study centers included were Memorial Sloan Kettering Cancer Center, Cedars-Sinai Medical Center, Emory Winship Cancer Institute, Houston Methodist Cancer Center, Henry Ford Cancer Institute, and University of Pittsburgh Medical Center. Results: Data on 26 patients were available for initial analyses. Mean age was 68 years; 58% were female and 65% Caucasian. 54% of patients had stage IV disease at first diagnosis, and 17%, 65%, and 17% had index ECOG score of 0, 1, and 2, respectively. Common genetic mutations include KRAS (40%) and TP53 (40%). Prior to liposomal irinotecan, treatments received for metastatic disease include gemcitabine+nab-paclitaxel (77%) and fluorouracil (5-FU)/leucovorin (LV)+irinotecan+oxaliplatin (19%). Patients had received 0 (12%), 1 (23%), and ≥2 (65%) lines of therapy in the metastatic setting prior to liposomal irinotecan. Mean duration of liposomal irinotecan use was 3.0 months; liposomal irinotecan was mostly received with 5-FU (23%) or 5-FU/LV (69%). Median rwOS was 4.9 months (95% CI: 3.0, 6.3). Conclusions: Real-world data of the first 26 patients in this study show patients treated with liposomal irinotecan are older, sicker, and have had more lines of therapy than previously reported in RCT data.

Characteristics of Women Presenting at the Emergency Department Who Choose Not to Disclose Being Subjected to Intimate Partner Violence

2021 ◽  
pp. 088626052199794
Author(s):  
Liat Lustig ◽  
Elina Fishenson ◽  
Merav Ben Natan
Keyword(s):  
Emergency Department ◽  
Domestic Violence ◽  
Intimate Partner Violence ◽  
Partner Violence ◽  
Chart Review ◽  
Medical Center ◽  
Intimate Partner ◽  
Study Characteristics ◽  
Trauma Informed ◽  
Review Study

Literature suggests that some women refrain from disclosing being subjected to intimate partner violence (IPV) upon their contact with the health care system. Such disclosure becomes critical when the violence compels women to seek urgent medical care. The purpose of the present study was to compare characteristics of women who disclose and women who do not disclose being subjected to domestic violence, when presenting at the Emergency Department (ED). In this chart review study, characteristics of 56 randomly sampled women who disclosed and 50 who did not disclose being subjected to domestic violence, when presenting at the ED in a medical center located in central-northern Israel between 2015 and 2018, were compared. It was found that women who did not disclose were more likely to be pregnant, legally defined as helpless, and dependent on others to some extent. In addition, they were more likely to be hospitalized, which may indicate a more severe injury, and were more likely to have been subjected to psychological abuse or neglect alone. A trauma informed approach should guide specific interventions with a focus on women with these characteristics in the ED, in order to facilitate their disclosure of IPV.

Sign in / Sign up

Export Citation Format

Share Document